**Figure S3.** CB-011 cells exhibit *in vitro* antitumor activity against PBMCs from patients with multiple myeloma.

(A) T cell cytotoxicity assay at a range of E:T ratios of CB-011 cells (green lines) or negative T cell control DKO cells (black lines) against PBMCs from samples from patients with multiple myeloma. (B) The AUC of data in panel A (x-axis [E:T ratios] vs y-axis [percentage of specific cell lysis]). (C) Dot plot representing the gating strategy to identify multiple myeloma cells in the PBMC samples. (D) Histogram showing expression of BCMA in PBMC samples (BCMA fluorescence minus one [FMO] in grey, samples in black). (E) BCMA density on PBMCs from samples from patients with multiple myeloma and MM.1S as a reference control.

AUC, area under the curve; BCMA, B cell maturation antigen; DKO, double knockout; E:T, effector to target; PBMC, peripheral blood mononuclear cell.